feat0

Positive Pinoy: my personal journey with HIV.

I was diagnosed last March 29, 2012 in a time that I was supposed to leave the country in a couple more weeks. I had my medical exam, and the result returned POSITIVE. From then on, my journey with HIV began.

Read More
feat2

What's New?: gateway to useful links on local and international news and updates about HIV.

A summary collection of medical articles, research news, and science breakthroughs on HIV/AIDS, STIs, and other related diseases.

Read More
feat3

HIV 101: Basic information for the newly-diagnosed.

Understand the basics, know the facts, and take care of yourself. This section contains basic information about HIV/AIDS.

Read More
feat4

Social Media: going viral against HIV/AIDS and other STIs.

The entrance of social media in spreading awareness about HIV/AIDS has gone viral. Famous personalities and the common man alike showed their support not just to HIV education but also with regards to the lives and struggles of the LGBT community.

Read More
feat5

Health Events: listing of wellness and advocacy events for HIV-positive individuals and friends.

This section contains a summary listing of knowledge-sharing events on HIV, mass HIV testing, and other wellness events that will strengthen the overall health of HIV-positive individuals.

Read More

24) US approves once-a-day pill to treat HIV




WASHINGTON DC - A new pill to treat HIV infection -- combining two previously approved drugs plus two new ones -- has been approved for adults living with the virus that causes AIDS, US regulators said Monday.

The single daily dose of Stribild provides a complete treatment regimen for HIV infection, the US Food and Drug Administration said in a statement.

"Through continued research and drug development, treatment for those infected with HIV has evolved from multi-pill regimens to single-pill regimens," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

"New combination HIV drugs like Stribild help simplify treatment regimens."

The new regimen, made by Gilead Sciences in California, was tested in more than 1,400 patients, in two double-blind clinical trials.

Results showed that Stribild performed as well or better than two other treatment combinations, and brought virus readings down to undetectable levels in around nine of 10 patients after 48 weeks.

The drug combines Truvada -- another Gilead offering approved in 2004, that combines emtricitabine and tenofovir disoproxil fumarate to fight an enzyme that HIV needs to replicate -- with elvitegravir, another enzyme-fighting drug, and cobicistat, which enhances the effects of elvitegravir.

The drug was tested in adult patients not previously treated for HIV. The FDA said further study is required to determine the drug's safety for women and children, how resistance may develop, and whether the drug interacts with other drugs.


Sources: